soul trial semaglutide Novo Nordisk's lowers MACE risk in soul trial oral semaglutide cardiovascular

The most common are digestive issues (stomach-related), particularly when first starting treatment or after increasing the dose

The price was better than anywhere else I looked

The first month is often an adjustment period, but "adjusting" should not become a reason to dismiss significant symptoms

J Clin Endocrinol Metab (2013) 98:344653

58 GLP-1RAs potentially may reduce the risk of AF onset and progression through direct and indirect effects on atrial remodelling, including a reduction in systemic inflammation, improvement of cardiomyocyte metabolism, autonomic nervous system modulation, regulation of intracellular Ca 2+ levels and prevention and possibly reversion of atrial fibrosis